NSE: MEDANTA | BSE: 543654

Expensive Performer

Download real time

1316.90 -15.30 (-1.15%)

37.75% Gain from 52W Low

60,551 NSE+BSE Volume

NSE 17 Jul, 2026 3:31 PM (IST)

35,407.7

Market Cap

High in industry

Beta 1Year

Very Low volatility

Global Health Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for MEDANTA, BSE:543654 Global Health Ltd.

Search Inside the pdf :

Global Health Ltd.

19 May 2026, 12:00AM

1316.90

-1.15%

Above par show, ramp-up of new units to drive earnings; maintain BUY

Buy: Global Health Ltd.

Target

Anand Rathi

Beating our estimate by 9/12/33%, Global Health (Medanta) reported 25/9/42% y/y surge in Revenue/EBITDA/PAT in Q4FY26 with 5% y/y increase in ARPOB to Rs66,687.

Global Health Ltd. has an average target of 1376.25 from 4 brokers.

Global Health Ltd.

18 May 2026, 12:00AM

1316.90

-1.15%

Global Health (MEDANTA IN) Q4FY26 Result Update Noida unit ramp-up on track BUY

Buy: Global Health Ltd.

Target

Prabhudas Lilladhar

Global Health's (MEDANTA) Q4FY26 EBITDA reported a 6% beat to our estimates with a growth of 13% YoY; largely aided by higher growth across Lucknow and Patna units. Further ramp up in Noida unit on track with losses reducing QoQ. MEDANTA's reported EBITDA growth of 7% CAGR over FY24-26, due to issues at Lucknow unit and start-up losses related to Noida unit in FY26. It has a total bed capacity of ~3,663 and intends to add ~3,190 beds over the next 3-4 years. With Lucknow unit issues largely resolved and ramp-up in Noida to be visible from Q2FY27E, EBITDA is expected to clock ~24% CAGR over FY26-28E. Our FY27 and FY28E EBITDA stands increased by 6%. Maintain...

Global Health has gained 20.88% in the last 3 Months

Global Health Ltd.

10 Feb 2026

1316.90

-1.15%

Ramp up of new units to drive earnings, maintain BUY

Buy: Global Health Ltd.

Anand Rathi

Global Health’ revenue (up 19% y/y) beat ARe/Ce by 6/3% in Q3FY26, while EBITDA (down 10% y/y) missed ARe/Ce by 4/8%. While PAT fell 8% y/y, APAT plunged 33.5%, owing to adjustment for labour code in the exceptional items.

Global Health Ltd. is trading above all available SMAs

Global Health Ltd.

06 Feb 2026

1316.90

-1.15%

Result Update:Global Health

Buy: Global Health Ltd.

Target

Axis Direct

We maintain our BUY rating on the stock.

Global Health Ltd. has an average target of 1376.25 from 4 brokers.

Global Health Ltd.

05 Feb 2026

1316.90

-1.15%

Lower-than-est. 3Q; Noida opex hits margins

Buy: Global Health Ltd.

Target

Motilal Oswal

Global Health (Medanta) exhibited higher-than-expected revenue for the quarter. However, EBITDA/PAT was lower than estimated (9%/18% miss), largely due to higher opex related to the Noida scale-up.

Global Health has gained 20.88% in the last 3 Months

Global Health Ltd.

05 Feb 2026

1316.90

-1.15%

Global Health (MEDANTA IN) Q3FY26 Result Update Faster ramp up in Noida unit will be key BUY

Buy: Global Health Ltd.

Prabhudas Lilladhar

MEDANTA's Q3FY26 EBITDA was largely in line with growth of 9% YoY. MEDANTA's EBITDA growth over FY24-26E is likely to be moderate at 8% CAGR, due to issues at Lucknow unit and start-up losses related to Noida unit in FY26. It has a total bed capacity of ~3,579 and intends to add ~2,800 beds over the next 4 years. With Lucknow unit issues largely resolved and ramp-up in Noida to be visible from Q2FY27E, EBITDA is expected to clock ~19% CAGR over FY26-28E. Maintain BUY' rating on MEDANTA with TP of Rs1,375/share,...

Global Health has gained 20.88% in the last 3 Months

Global Health Ltd.

26 Nov 2025

1316.90

-1.15%

Expanding the Care canvas - a long runway for growth ahead!

Buy: Global Health Ltd.

Motilal Oswal

We analyzed the supply-demand dynamics of hospitals in the Noida/Greater Noida regions, given the recently commissioned hospital of Medanta.

Global Health has gained 20.88% in the last 3 Months

Global Health Ltd.

11 Nov 2025

1316.90

-1.15%

Result Update:Global Health

Buy: Global Health Ltd.

Target

Axis Direct

We maintain a BUY rating on the stock.

Global Health Ltd. is trading above all available SMAs

Global Health Ltd.

10 Nov 2025

1316.90

-1.15%

Healthy growth in patient volume and realization

Buy: Global Health Ltd.

Target

Motilal Oswal

Global Health (Medanta) delivered better-than-expected revenue (9% beat) in 2QFY26. However, it delivered marginally lower-than-expected EBITDA/PAT (3%/2% miss) for the quarter.

Global Health Ltd. has an average target of 1376.25 from 4 brokers.

Global Health Ltd.

11 Aug 2025

1316.90

-1.15%

Result Update:Global Health

Buy: Global Health Ltd.

Target

Axis Direct

We maintain a BUY rating on Medanta, supported by the expected recovery from temporary business disruptions, improvement in ARPOB, and incremental bed capacity addition, including the Noida hospital, which is likely to be operational by the end of H1FY26E.

Global Health Ltd. is trading above all available SMAs

VOTE: Is Global Health Ltd. worth buying?

91 Votes:

Buy 79.12%

Sell 12.09%

Hold 8.79%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf